PNEUMOSIL

About:

• It has been developed by the Serum Institute of India Private Limited (SIIPL) in collaboration with partners like the Bill and Melinda Gates Foundation.
  
  
• SIIPL developed and got the license of the first indigenous Pneumococcal Conjugate Vaccine (PCV) from the Government of India during COVID-19 pandemic lock-down.
  
  
• This Indigenous Pneumococcal Conjugate Vaccine will be available in the market under the brand name "Pneumosil" at an affordable price in a single dose (vial and pre-filled syringe) and Multidose (vial) presentations.
  
  
• Pneumosil is effective in the prevention of Pneumonia disease.